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Abstract 
Loss of genetic material from the long arm of 
chromosome 9 is a common finding in patients with 
hematological malignancies. These deletions can 
result from true loss of 9q or complex 
rearrangements such as dicentric chromosomes,  
unbalanced translocations, and formation of an 
isochromosome of the short arm of chromosome 9. 
Isochromosome i(9)(p10) is an infrequent event that 
has been described mainly in myeloid malignancies 
and B-cell lymphomas. 
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Figure 1. Partial karyotypes with i(9)(p10) (A). Fluorescence in situ hybridization with LSI CDKN2A/CEP9 probe (Vysis/Abott 
molecular, US) showing 3 copies of CDKN2A located on 9p (red signal) as a result of isochromosome formation (B). 
Hybridization with whole chromosome 9 probe (Metasystems, Germany) showing 1 normal chromosome 9 and the der(9) 
chromosome (green signal) (C). 
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Clinics and pathology 
Disease 
Myeloid malignancies mainly, acute lymphoblastic 
leukemia (ALL) and lymphomas. 
Phenotype/cell stem origin 
Found in chronic and acute myeloid malignancies 
and mainly B-cell lymphoid malignancies. 
Etiology 
Chronic myeloid malignancies  in 12 (7M/5F aged 
43 to 87 years, median 57 years): 1 chronic 
myeloproliferative disorder (MPD) (Hoo et al., 
1987), 4 polycythemia vera (PV) (Chen et al., 1998; 
Najfeld et al., 2007) and 7 myelodysplastic 
syndrome (MDS) patients (Billstrom et al., 1988; 
Smadja et al., 1988; Iurlo et al., 1989; Wang et al., 
1997; Lindvall et al., 2001; Stamatoullas et al., 2006; 
Najfeld et al., 2007). Among them, 3 patients 
developed MDS after chemotherapy for multiple 
myeloma (Smadja et al.,1988;  Iurlo et al., 1989) or 
chronic lymphocytic leukemia (Wang et al., 1997).  
Acute myeloid leukemia  in 9 (4M/5F aged 13 to 79 
years, median 67 years): 1 acute myeloblastic 
leukemia with maturation (AML-M2) (Poppe et al., 
2004), 2 acute myelomonocytic leukemia (AML-
M4) (Adriaansen et al., 1988; Poppe et al., 2004), 1 
acute monoblastic leukemia without differentiation 
(AML-M5a) (Negrini et al., 1995), 1 acute 
megakaryoblastic leukemia (AML-M7) (Teyssier et 
al., 1987) and 4 acute myeloid leukemia, NOS 
(Pedersen et al., 1997; Van Limbergen et al., 2002; 
Shali et al., 2006; Moosavi et al., 2009). 1 of them 
developed acute myeloid leukemia 1 year after a 
myeloproliferative disorder was diagnosed (Negrini 
et al., 1995).  
Acute lymphoblastic leukemia  in 5 (4M/1F  aged 
10 and 14 years, 3 unknown); 3 patients were 
diagnosed with B-ALL  (Heerema et al., 1992; 
Paulsson et al., 2015; Coyaud et al 2010) and 2 with 
T-ALL (Gladstone et al., 1998).  
B-cell lymhoma  in 13: diffuse large B-cell 
lymphoma (DLBCL) in 6 (3M/3F aged 18, 70, 73. 
81 and 83 years, 2 unknown) (Mark et al., 1979; 
Mikraki et al., 1992; Ruminy et al., 2006; Chapiro et 
al., 2008; Bacher et al., 2011; Narayan et al., 2013), 
Hodgkin disease in 6 (3M/3F aged 12, 21, 25, 25 and 
29 years, 1 unknown) (Tilly et al., 1991;  Dohner et 
al., 1992; Schlegelberger et al., 1994; Cook et al., 
2004) and a 62-years old male patient with 
extranodal marginal zone B-cell lymphoma (Van 
Roosbroeck et al., 2016).  
T-cell lymhoma  in 2: a 37- years old female 
diagnosed with angioimmunoblastic T-cell 
lymphoma (Lepretre et al., 2000) and a 78-years old 
female with adult T-cell lymphoma/leukemia 
(HTLV-1+) (Tanaka et al., 2001). 
Epidemiology 
41 patients; 22 males and 19 females aged 10 to 87 
years; median 67 years. 
Prognosis 
i(9)(p10) usually occurs within a complex 
karyotype, in itself with poor prognosis, therefore its 
appearance may be associated with advanced disease 
and unfavourable prognosis; the clinical significance 
of isolated i(9)(p10) in MPD is unclear. 
Genetics 
Note 
As an isochromosome 9p can be misinterpreted as 9q 
deletion, a much more common finding in 
hematological malignancies, fluorescence in situ 
hybridization with locus specific probes of 
chromosome 9p/9q is a helpful method to confirm 
this less frequent abnormality. 
Cytogenetics 
Note 
Similar to i(5)(p10), described mainly in MDS and 
AML, two types of i(9)(p10) are observed: i(9)(p10) 
resulting in a loss of the long arm of the chromosome 
9 (9q- and 9p trisomy) or it may be present as an 
extra +i(9)(p10), in addition to 2 normal 
chromosomes 9. 
Cytogenetics morphological 
Present as a supernumerary +i(9)(p10), in addition to 
two normal chromosomal 9 in 23 patients: 1 MPD 
(Hoo et al., 1987), 3 PV (Chen et al., 1998; Najfeld 
et al., 2007), 5 MDS (Billstrom et al., 1988; Smadja 
et al., 1988; Lindvall et al., 2001; Stamatoullas et al., 
2006; Najfeld et al., 2007), 3 AML (Teyssier et al., 
1987; Pedersen et al 1997; Van Limbergen et al., 
2002), 1 ALL (Coyaud et al., 2010) and 10 B-cell 
lymphomas (Tilly et al., 1991; Dohner et al., 1992; 
Mikraki et al., 1992; Schlegelberger et al., 1994; 
Cook et al., 2004; Ruminy et al., 2006; Chapiro et 
al., 2008; Bacher et al., 2011; Narayan et al., 2013; 
Van Roosbroeck et al., 2016). 
Additional anomalies 
Found as the sole extra i(9)(p10) in 1 MPD (Hoo et 
al., 1987) and 3 PV patients (Chen et al., 1998; 
Najfeld et al., 2007), in association with i(9)(q10) in 
1 PV (Najfeld et al., 2007) and 1 ALL (Heerema et 
al., 1992). Associated with chromosome 
5/chromosome 7 anomalies or their combination in 
5 MDS (Iurlo et al., 1989; Wang et al., 1997; 
Lindvall et al., 2001; Stamatoullas et al., 2006; 
Najfeld et al., 2007) and 6 AML (Teyssier et al., 
1987; Pedersen et al., 1997; Van Limbergen et al.,  
2002; Poppe et al., 2004; Shali et al., 2006; Moosavi 
et al., 2009) and found with t(9;11)(p21;q23) in 2 
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AML patients (Cuneo et al., 1993; Negrini et al., 
1995). Found with del(6q), del(7q) in 1, 
del(5q),del(6q) in 1 (Gladstone et al., 1998) and 
t(6;14)(p22;q32),+del(7q) in 1 ALL (Coyaud et al 
2010). Part of complex karyotypes associated with 
14q32 rearrangements in DLBCL and part of 
hypedriploid/near triploid complex karyotypes in 
Hodgkin disease patients. 




Isochromosome i(9)(p10) represents a rare but 
recurrent chromosome abnormality in hematological 
malignancies, especially in chronic myeloid 
disorders, acute myeloid leukemia and B-cell 
lymphomas such as DLBCL and Hodgkin disease. 
The formation of i(9)(p10) induce a loss of the long 
arm of the chromosome 9 and duplication of its short 
arm, or less frequently it results only in an extra copy 
of 9p when 2 normal chromosomes 9 are present. In 
both cases, gain of chromosome material from 9p 
leading to extra copies of a gene or genes appears to 
be important in disease pathogenesis via gene dosage 
effect. Among them, the tyrosine kinase gene JAK2 
on 9p24.1 might be a candidate gene as its numerical 
gain and structural rearrangements characterize both 
myeloid and B-lymphoid neoplasms. Gain and 
amplification of chromosomal sequences spanning 
JAK2 has been observed in both JAK2617V>F-
positive and -negative patients with Philadelphia 
chromosome negative myeloproliferative disorders, 
with or without +9/+9p chromosomal abnormalities, 
indicating that amplification of a genes on 9p, and 
not deletion of genes from 9q, may play a role in the 
pathogenesis (Najfeld et al., 2007). JAK2 copy gain 
is also one of the most common genetic alterations 
in B-lymphoid neoplasms, especially Hodgkin 
lymphoma and primary mediastinal large B-cell 
lymphoma (Van Roosbroeck et al., 2016). Several of 
the imbalances described, including a recurrent 
9p24.1 amplicon that includes JAK2 and 
immunoregulatory PD-1 ligand genes, leading to 
increased JAK2 protein expression activating the 
JAK2/STAT signaling pathway in a copy number-
dependent manner. 
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